Gemina Laboratories Ltd.
GLAB
CNSX
| 01/31/2025 | 10/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 143.26% | -15.99% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 63.20% | -10.31% | |||
| Operating Income | -63.20% | 10.31% | |||
| Income Before Tax | -57.97% | 9.95% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -57.97% | 9.95% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -57.97% | 9.95% | |||
| EBIT | -63.20% | 10.31% | |||
| EBITDA | -63.46% | 10.10% | |||
| EPS Basic | -57.65% | 11.46% | |||
| Normalized Basic EPS | -60.38% | 10.17% | |||
| EPS Diluted | -57.65% | 11.46% | |||
| Normalized Diluted EPS | -60.38% | 10.17% | |||
| Average Basic Shares Outstanding | 0.38% | 1.31% | |||
| Average Diluted Shares Outstanding | 0.38% | 1.31% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||